Treating MASH: Lifestyle, Medications, and Metabolic Care

Treating MASH is about more than just your liver; it is about managing your entire metabolic system. Because the liver is deeply connected to how your body processes energy, the most effective treatments address the “root causes” like obesity, type 2 diabetes, and high cholesterol ^[1][2].

The goal of treatment is twofold: to stop or reduce liver inflammation and to prevent the progression of fibrosis (scarring) ^[3].

The Foundation: Lifestyle and Weight Loss

Lifestyle changes remain a foundational treatment for MASH. While it can be difficult to sustain, weight loss offers a dose-related benefit for liver health ^[1].

• The 7–10% Target: Modest weight loss can reduce steatosis, but research shows that losing approximately 7% to 10% of your body weight can lead to a significant reduction in liver inflammation (MASH resolution) ^[4][1].
• The 10% Goal: For those with more advanced scarring, losing 10% or more of your body weight is more likely to improve fibrosis ^[5][3]. Note that these percentages are approximate study thresholds, not absolute guarantees; results vary, and established cirrhosis requires specialist supervision.
• Dietary Patterns: Experts recommend a Mediterranean-style diet, which is rich in vegetables, healthy fats (like olive oil), and lean proteins, while being low in processed sugars and saturated fats ^[6][1].
• Exercise: An individualized activity plan combining aerobic and resistance training provides benefits even if substantial weight loss is not achieved.
• Alcohol: For individuals with clinically significant fibrosis, cirrhosis, or alcohol-related disease, abstinence is especially important ^[1]. If you drink heavily or may be physically dependent on alcohol, seek medical help before stopping to ensure withdrawal safety.

Targeted Medication: Resmetirom (Rezdiffra)

In March 2024, the FDA granted accelerated approval to resmetirom, the first medication specifically indicated for adults with noncirrhotic MASH with moderate-to-advanced liver scarring (stages F2 to F3) ^[7][1]. It is an oral pill that works by activating a thyroid hormone receptor in the liver to help the body break down excess fat ^[8].

• Efficacy: The approval was based on histologic surrogate endpoints at trial time points showing the drug improved trial measures of MASH resolution and/or fibrosis by at least one stage in selected patients ^[9]. It does not replace diet and exercise, is not a cure, and requires specialist assessment.
• Dosing: The dose is weight-based: 80 mg once daily for people weighing under 100 kg, and 100 mg once daily for people weighing 100 kg or more ^[10].
• Important Safety Context: Resmetirom is not recommended for patients with decompensated cirrhosis ^[11][7]. It carries warnings for hepatotoxicity (drug-induced liver injury) and gallbladder events, and has clinically important interactions with certain statins and CYP2C8/OATP-interacting drugs ^[8]. The most common side effects are diarrhea and nausea ^[8]. Treatment requires careful medication review and monitoring by the prescriber.

Managing Metabolic “Co-Conditions”

If you have other metabolic health issues, your doctor may use medications that treat those conditions. While some offer “bonus” benefits for the liver, they must be prescribed appropriately:

• GLP-1 Receptor Agonists (e.g., Semaglutide): Often appropriate for type 2 diabetes and obesity, these medications help with significant weight loss and may improve liver disease through that weight loss, but they are not automatically established MASH treatments ^[12][1].
• SGLT2 Inhibitors: These are used for diabetes, heart failure, and kidney protection. They have promising metabolic and steatosis data but are not established liver-specific therapy for histologic MASH ^[13][14].
• Pioglitazone & Vitamin E: In carefully selected populations, pioglitazone (a diabetes medication) or high-dose Vitamin E may be used ^[15][16]. However, pioglitazone carries risks of weight gain, edema, and heart-failure concerns ^[17], and high-dose vitamin E carries debated long-term risks, including bleeding or prostate-cancer concerns ^[16]. Verify current regulatory status with your doctor.

Surgical and Specialized Options

For eligible patients who struggle to lose weight through diet and exercise alone, metabolic/bariatric surgery is an option ^[18]. Studies show that weight-loss surgery in selected populations can lead to the resolution of MASH and can even improve fibrosis in many cases ^[19]. Eligibility has evolved and depends on comorbidities, operative risk, and whether cirrhosis is compensated; surgery in decompensated cirrhosis generally requires transplant-center assessment and is not routine.

Choosing a treatment plan is a collaborative process. Whether through lifestyle, new medications like resmetirom, or metabolic surgery, the focus is on reducing the stress on your liver and giving it the best chance to heal ^[1].